Safety Standards
Kedrion Biopharma continuously seeks the highest standards in quality, safety, and processes.
Koate-DVI is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.
Learn More
How to Order
For Hemophilia Treatment Centers eligible for PHS pricing, call the Kedrion customer service team at 1-855-353-7466
Learn More
Introducing the Koāte-DVI TRY-IT Program
The Koāte-DVI TRY IT Program offers qualifying patients up to 2 weeks of free Koāte-DVI.
Learn More

Koāte®-DVI [Antihemophilic Factor (Human)]

Koāte-DVI is a human plasma-derived factor VIII replacement therapy that is indicated to treat patients with hemophilia A for over 10 years. Koāte-DVI is proven to rapidly increase levels of factor VIII and to stop bleeding episodes.1 Koāte-DVI has a low risk for side effects, is manufactured with dedicated steps to inactivate or remove viruses, and is available in a range of dosing strengths for use at home or at a doctor’s office.


Reference:  1. Powell JS, Bush M, Harrison J, Abildgaard C, Vosburgh E, Thompson AR, Hurst D. Safety and efficacy of solvent/detergent- treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A. Haemophilia. 2000;6(3):140-9.